120 related articles for article (PubMed ID: 2654814)
1. Lymphoproliferative syndrome associated with c-myc expression driven by a class I gene promoter in transgenic mice.
Morello D; Lavenu A; Bandeira A; Portnoi D; Gaillard J; Babinet C
Oncogene Res; 1989; 4(2):111-25. PubMed ID: 2654814
[TBL] [Abstract][Full Text] [Related]
2. Tissue-specific post-transcriptional regulation of c-myc expression in normal and H-2K/human c-myc transgenic mice.
Morello D; Asselin C; Lavenu A; Marcu KB; Babinet C
Oncogene; 1989 Aug; 4(8):955-61. PubMed ID: 2668846
[TBL] [Abstract][Full Text] [Related]
3. Different regulation of class I gene expression in the adult mouse and during development.
Drezen JM; Nouvel P; Babinet C; Morello D
J Immunol; 1992 Jul; 149(2):429-37. PubMed ID: 1624790
[TBL] [Abstract][Full Text] [Related]
4. Oncogene expression in autoimmune mice.
Mountz JD; Mushinski JF; Mark GE; Steinberg AD
J Mol Cell Immunol; 1985; 2(3):121-31. PubMed ID: 3916923
[TBL] [Abstract][Full Text] [Related]
5. The 5' and 3' non-coding sequences of the c-myc gene, required in vitro for its post-transcriptional regulation, are dispensable in vivo.
Morello D; Lavenu A; Pournin S; Babinet C
Oncogene; 1993 Jul; 8(7):1921-9. PubMed ID: 8510935
[TBL] [Abstract][Full Text] [Related]
6. The transgenic window on lymphoid malignancy.
Adams JM; Harris AW; Vaux DL; Alexander WS; Rosenbaum H; Klinken SP; Strasser A; Bath ML; McNeall J; Cory S
Princess Takamatsu Symp; 1989; 20():297-309. PubMed ID: 2518688
[TBL] [Abstract][Full Text] [Related]
7. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
Roland J; Morello D
Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795
[TBL] [Abstract][Full Text] [Related]
8. Expression of cellular oncogenes: unrearranged c-myc gene but altered promoter usage in radiation-induced thymoma.
Bandyopadhyay SK; D'Andrea E; Fleissner E
Oncogene Res; 1989; 4(4):311-8. PubMed ID: 2475843
[TBL] [Abstract][Full Text] [Related]
9. A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice.
Nussenzweig MC; Schmidt EV; Shaw AC; Sinn E; Campos-Torres J; Mathey-Prevot B; Pattengale PK; Leder P
Nature; 1988 Dec; 336(6198):446-50. PubMed ID: 3143076
[TBL] [Abstract][Full Text] [Related]
10. Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1988; 3(3):271-9. PubMed ID: 3144697
[TBL] [Abstract][Full Text] [Related]
11. Cellular oncogenes and lymphocyte activation.
Schneider-Schaulies J; Knauer R; Schimpl A; Wecker E
Behring Inst Mitt; 1987 Jun; (81):110-9. PubMed ID: 3115245
[TBL] [Abstract][Full Text] [Related]
12. The cis-acting elements known to regulate c-myc expression ex vivo are not sufficient for correct transcription in vivo.
Lavenu A; Pournin S; Babinet C; Morello D
Oncogene; 1994 Feb; 9(2):527-36. PubMed ID: 8290263
[TBL] [Abstract][Full Text] [Related]
13. Exogenous c-myc gene overexpression interferes with early events in F9 cell differentiation.
Onclercq R; Babinet C; Cremisi C
Oncogene Res; 1989; 4(4):293-302. PubMed ID: 2671866
[TBL] [Abstract][Full Text] [Related]
14. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
[TBL] [Abstract][Full Text] [Related]
15. Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1989; 4(4):253-8. PubMed ID: 2549487
[TBL] [Abstract][Full Text] [Related]
16. Hemopoietic neoplasms in lethally irradiated mice repopulated with bone marrow cells carrying the human c-myc oncogene: a repopulation assay.
Hirabayashi Y; Inoue T; Suda Y; Aizawa S; Ikawa Y; Kanisawa M
Exp Hematol; 1992 Feb; 20(2):167-72. PubMed ID: 1544384
[TBL] [Abstract][Full Text] [Related]
17. Oncogene-induced liver neoplasia in transgenic mice.
Sandgren EP; Quaife CJ; Pinkert CA; Palmiter RD; Brinster RL
Oncogene; 1989 Jun; 4(6):715-24. PubMed ID: 2543942
[TBL] [Abstract][Full Text] [Related]
18. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.
Santoni-Rugiu E; Nagy P; Jensen MR; Factor VM; Thorgeirsson SS
Am J Pathol; 1996 Aug; 149(2):407-28. PubMed ID: 8701981
[TBL] [Abstract][Full Text] [Related]
19. Positive selection of thymocytes expressing the same TCR by different MHC ligands results in the production of functionally distinct thymocytes distinguished by differential expression of the heat stable antigen.
Teh HS; Motyka B; Teh SJ
J Immunol; 1998 Jan; 160(2):718-27. PubMed ID: 9551907
[TBL] [Abstract][Full Text] [Related]
20. The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).
Lavialle C; Modjtahedi N; Lamonerie T; Frebourg T; Landin RM; Fossar N; Lhomond G; Cassingena R; Brison O
Anticancer Res; 1989; 9(5):1265-79. PubMed ID: 2686529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
